# MLYS catalysts: Mineralys Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mlys/catalysts

> Mineralys Therapeutics, Inc. (MLYS) has 1 upcoming catalyst. The next is the lorundrostat PDUFA date, December 22, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MLYS?

Mineralys Therapeutics, Inc. (MLYS) has 1 upcoming catalyst. The next is the lorundrostat PDUFA date, December 22, 2026. Press release filed with the SEC (EX-99): "- Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 -" [Calendar and source filings](https://sec-api.dev/companies/mlys/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001933414-26-000142, https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/mlys/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Mineralys Therapeutics, Inc. |
| Ticker | MLYS (Nasdaq) |
| SEC CIK | 1933414 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mlys |

## Cash runway

Cash $101.3M as of 2026-09-30; quarterly burn $43.1M; about 7.0 months of runway at that rate (XBRL company facts, accession 0001933414-26-000144).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 11, 2024 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys3q248kex991.htm)) |
| Q1 2025 | [Lorundrostat trial start](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | scheduled | "Other indications: We anticipate initiating our Phase 2 clinical trial (Explore-OSA) in the first quarter of 2025, which is planned to evaluate the safety and efficacy of lorundrostat 50 mg QD in approximately 40 subjects with moderate-to-severe OSA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000009/mlys-20241231.htm)) |
| 1H 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | scheduled | ""We are excited that the two pivotal trials from this program are fully enrolled and on track to deliver topline data during the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys3q248kex991.htm)) |
| February 12, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlysfy248kex991.htm)) |
| Mar 2025 | [Mineralys Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | scheduled | "•Pivotal Advance-HTN Trial - Anticipate reporting topline data in March 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlysfy248kex991.htm)) |
| Mar 2025 | [Mineralys Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | scheduled | "- Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlysfy248kex991.htm)) |
| March 10, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "On March 10, 2025, the Company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000162828025011459/mlys-20250310.htm)) |
| March 29, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "Following the recently announced positive topline data from both Advance-HTN and Launch-HTN pivotal trials, detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys202503318kex991.htm)) |
| Q2 2025 | [Mineralys Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | scheduled | "- Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm)) |
| Q2 2025 | [Mineralys Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | scheduled | ""We are pleased to have completed enrollment in Explore-CKD and be on track to share topline data in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/mlys202502048kex991.htm)) |
| May 12, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm)) |
| June 17, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "On June 17, 2025, the Company announced positive topline data from its Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in subjects with hypertension and comorbid CKD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000070/mlys-20250617.htm)) |
| August 12, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys2025q28kex991.htm)) |
| Q4 2025 | [Lorundrostat NDA/BLA submission](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | scheduled | "With the success of our two pivotal trials, we are working toward submitting our new drug application with a pre-NDA meeting with the FDA anticipated in the fourth quarter of 2025," stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm)) |
| November 10, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm)) |
| December 17, 2025 | [Lorundrostat primary completion](https://sec-api.dev/pdufa/lorundrostat) | MLYS | Obstructive Sleep Apnea; Hypertension | completed | "NCT06785454 (A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06785454)) |
| December 22, 2025 | [Lorundrostat NDA/BLA submission](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension in combination with other antihypertensive drugs | completed | "We submitted our NDA for lorundrostat to the FDA on December 22, 2025, and we have not yet received regulatory approval from the FDA or from other regulatory jurisdictions." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)) |
| December 30, 2025 | [Lorundrostat primary completion](https://sec-api.dev/pdufa/lorundrostat) | MLYS | Hypertension | completed | "NCT05968430 (Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05968430)) |
| Q1 2026 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS | moderate to severe obstructive sleep apnea and hypertension | scheduled | "On January 6, 2026, the Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safety and efficacy of lorundrostat in participants with moderate to severe obstructive sleep apnea and hypertension, in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys-20260106.htm)) |
| 1H 2026 | [Mineralys Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | scheduled | "- Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys2025q28kex991.htm)) |
| March 9, 2026 | [Aldosterone NDA/BLA acceptance](https://sec-api.dev/pdufa/aldosterone) | MLYS |  | completed | "RADNOR, Pa., March 9, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys202603068kex991.htm)) |
| March 9, 2026 | [Lorundrostat NDA/BLA acceptance](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension | completed | "On March 9, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and topline results from the Company's Phase 2 Explore-OSA exploratory trial." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm)) |
| March 12, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm)) |
| May 6, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys2026q18kex991.htm)) |
| August 5, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm)) |
| October 29, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm)) |
| December 22, 2026 | [Lorundrostat PDUFA date](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension in combination with other antihypertensive drugs | scheduled | "- Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm)) |

## Drugs

- [Aldosterone](https://sec-api.dev/pdufa/aldosterone): 
- [Lorundrostat](https://sec-api.dev/pdufa/lorundrostat): hypertension in combination with other antihypertensive drugs, hypertension in participants with hypertension and comorbid ckd, hypertension, moderate to severe obstructive sleep apnea and hypertension, hypertension and comorbid ckd, Obstructive Sleep Apnea

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mlys/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MLYS catalysts: Mineralys Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mlys/catalysts

```bibtex
@misc{secapidev_companies_mlys_catalysts_20261116,
  title        = {MLYS catalysts: Mineralys Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mlys/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mlys_catalysts_20261116","title":"MLYS catalysts: Mineralys Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mlys/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
